California Oncology Weekly Newsletter 7.11.2017

Blog Pic

This Weekly’s Hot Topics

  • Fellows in California are invited to submit abstracts for their original research. California News
  • The City of Chicago recently released a draft of the disclosure log. National News
  • Participate in the Oncology Patient Engagement Trend Report survey! Affiliate News

California has not been known to be the most “business friendly” state in the union in recent history. We recently wrote about California Senate Bill 790 passing in the California state senate that was intended to restrict pharmaceutical companies from giving gifts and incentives to medical professionals. The bill prohibits manufacturers from offering or giving a gift to a health care provider. The bill also prohibits a manufacturer or an entity on behalf of a manufacturer from providing a fee, payment, subsidy, or other economic benefit to a health care provider in connection with the provider’s participation in research. For more information click here and go to California News.

The Department of Fair Employment and Housing (DFEH) have updates to mandatory California labor law posting requirements that affect your business. In order for your business to stay in compliance with these recent changes, the updated postings must be downloaded, printed, and then posted next to your current labor law poster. For more information click here and go to California News.

MOASC President, Warren H. Fong, M.D. attended the Carrier Advisory Committee meeting on June 28, 2017 in Los Angeles. For more information click here and go to Noridian News.

In the June 27, 2017 edition of the California Oncology Weekly, MOASC asked for your feedback on Blue Shield’s pilot cancer care program (Blue Shield Letter). MOASC shared their concern with ASCO & COA, the CMA and the California Department of Managed Health Care (DMHC) expressing concern, noting the negative impact on the oncology community, asking for more details about the program and Blue Shield’s future intents. For more information click here and go to DMHC News.

The City of Chicago recently released a draft of the disclosure log pharmaceutical representatives will be expected to use to keep track of the interactions they have with Chicago physicians. The form requires pharmaceutical representatives to log the following information with respect to any interactions they have with physicians within city limits: HCP first name; HCP middle initial/name; HCP last name; HCP name suffix (i.e., Jr.); HCP primary business address; HCP license type (i.e., MD, DO, etc.); HCP state license number; HCP NPI (if applicable); date of interaction; location of interaction; duration of interaction; pharmaceuticals promoted; whether samples were provided, and if so, the quantity of samples given and the value of such samples; whether pharmaceutical-related materials were given, if so, the value of the materials given; and whether any other items of value or compensation were given, if so, what type and the combined value of other items.  For more information click here and go to National News.

To view the complete California Oncology Weekly Newsletter go to the date below.

July 11, 2017

No comments have been posted yet.